936727-44-5

Usage

Uses

Used in Organic Synthesis:
1-(Benzofuran-5-yl)cyclopropanecarboxylic acid is used as a building block for the synthesis of various organic compounds. Its unique structure allows for the creation of a wide range of chemical entities with potential applications in different fields.
Used in Pharmaceutical Industry:
1-(Benzofuran-5-yl)cyclopropanecarboxylic acid is used as a key intermediate in the development of pharmaceuticals. Its potential biological activities make it an important target for drug discovery and development, contributing to the creation of new medicines with therapeutic benefits.
Used in Medicinal Chemistry:
1-(Benzofuran-5-yl)cyclopropanecarboxylic acid is utilized in medicinal chemistry for the design and synthesis of novel compounds with potential therapeutic properties. Its reactivity and structural features facilitate the exploration of new chemical space for the development of innovative drugs.

Upstream product

• 779199-69-8 1-(4-hydroxyphenyl)cyclopropanecarboxylic acid methyl ester 
• 779206-51-8 1-(4-methoxyphenyl)cyclopropanecarboxylic acid methyl ester 
• 16728-01-1 1-(4-methoxyphenyl)-1-cyclopropanecarboxylic acid 

Downstream Products

• 936727-45-6 1-(2,3-dihydrobenzofuran-5-yl)cyclopropanecarboxylic acid 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF CFTR

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.